These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37146620)

  • 1. Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer - Authors' reply.
    Johnston SRD; Tolaney SM; O'Shaughnessy J; Rastogi P; Harbeck N; Martin M
    Lancet Oncol; 2023 Jun; 24(6):e238. PubMed ID: 37146620
    [No Abstract]   [Full Text] [Related]  

  • 2. Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer.
    Meirson T; Goldstein DA; Gyawali B; Tannock IF
    Lancet Oncol; 2023 Jun; 24(6):589-593. PubMed ID: 37146621
    [No Abstract]   [Full Text] [Related]  

  • 3. Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy-Reply.
    Wei RJ; Martin M; Johnston SRD
    JAMA Oncol; 2022 Nov; 8(11):1702. PubMed ID: 36173623
    [No Abstract]   [Full Text] [Related]  

  • 4. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
    Johnston SRD; Harbeck N; Hegg R; Toi M; Martin M; Shao ZM; Zhang QY; Martinez Rodriguez JL; Campone M; Hamilton E; Sohn J; Guarneri V; Okada M; Boyle F; Neven P; Cortés J; Huober J; Wardley A; Tolaney SM; Cicin I; Smith IC; Frenzel M; Headley D; Wei R; San Antonio B; Hulstijn M; Cox J; O'Shaughnessy J; Rastogi P;
    J Clin Oncol; 2020 Dec; 38(34):3987-3998. PubMed ID: 32954927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Fleming GF; Pagani O; Regan MM; Walley BA; Francis PA
    Ann Oncol; 2022 Jun; 33(6):658. PubMed ID: 35301096
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
    Tolaney SM; Guarneri V; Seo JH; Cruz J; Abreu MH; Takahashi M; Barrios C; McIntyre K; Wei R; Munoz M; Antonio BS; Liepa AM; Martin M; Johnston SRD; Kellokumpu-Lehtinen PL; Harbeck N
    Eur J Cancer; 2024 Mar; 199():113555. PubMed ID: 38244363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
    Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
    Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abemaciclib plus fulvestrant for breast cancer.
    Stirrups R
    Lancet Oncol; 2019 Nov; 20(11):e617. PubMed ID: 31587880
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1.
    Toi M; Boyle F; Im YH; Reinisch M; Molthrop D; Jiang Z; Wei R; Sapunar F; Grimes BR; Nabinger SC; Johnston SRD
    Oncologist; 2023 Jan; 28(1):e77-e81. PubMed ID: 36342342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
    Rugo HS; O'Shaughnessy J; Boyle F; Toi M; Broom R; Blancas I; Gumus M; Yamashita T; Im YH; Rastogi P; Zagouri F; Song C; Campone M; San Antonio B; Shahir A; Hulstijn M; Brown J; Zimmermann A; Wei R; Johnston SRD; Reinisch M; Tolaney SM;
    Ann Oncol; 2022 Jun; 33(6):616-627. PubMed ID: 35337972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Harbeck N; Rastogi P; Martin M; Tolaney SM; Shao ZM; Fasching PA; Huang CS; Jaliffe GG; Tryakin A; Goetz MP; Rugo HS; Senkus E; Testa L; Andersson M; Tamura K; Del Mastro L; Steger GG; Kreipe H; Hegg R; Sohn J; Guarneri V; Cortés J; Hamilton E; André V; Wei R; Barriga S; Sherwood S; Forrester T; Munoz M; Shahir A; San Antonio B; Nabinger SC; Toi M; Johnston SRD; O'Shaughnessy J;
    Ann Oncol; 2021 Dec; 32(12):1571-1581. PubMed ID: 34656740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
    Giordano SH; Freedman RA; Somerfield MR;
    J Clin Oncol; 2022 Jan; 40(3):307-309. PubMed ID: 34878801
    [No Abstract]   [Full Text] [Related]  

  • 13. Abemaciclib: First Global Approval.
    Kim ES
    Drugs; 2017 Dec; 77(18):2063-2070. PubMed ID: 29128965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.
    Tolaney SM; Sahebjam S; Le Rhun E; Bachelot T; Kabos P; Awada A; Yardley D; Chan A; Conte P; Diéras V; Lin NU; Bear M; Chapman SC; Yang Z; Chen Y; Anders CK
    Clin Cancer Res; 2020 Oct; 26(20):5310-5319. PubMed ID: 32694159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor.
    Gebbia V; Valerio MR; Firenze A; Vigneri P
    Expert Opin Drug Saf; 2020 Aug; 19(8):945-954. PubMed ID: 32552035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Agent Abemaciclib Active in Breast Cancer.
    Cancer Discov; 2016 Aug; 6(8):809-10. PubMed ID: 27354271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.
    Hamilton E; Cortes J; Ozyilkan O; Chen SC; Petrakova K; Manikhas A; Jerusalem G; Hegg R; Huober J; Zhang W; Chen Y; Martin M
    Breast Cancer Res Treat; 2022 Aug; 195(1):55-64. PubMed ID: 35829935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy.
    Sun R; Wei LJ
    JAMA Oncol; 2022 Nov; 8(11):1701. PubMed ID: 36173642
    [No Abstract]   [Full Text] [Related]  

  • 19. Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib.
    Omarini C; Molinaro E; Barbolini M; Dominici M; Piacentini F
    Breast; 2020 Aug; 52():132-133. PubMed ID: 32512359
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter to the Editor for 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study'.
    Harbeck N; Rastogi P; Shahir A; Johnston S; O'Shaughnessy J
    Ann Oncol; 2022 Feb; 33(2):227-228. PubMed ID: 34756989
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.